Navigation Links
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Date:4/2/2009

PHILADELPHIA, April 2 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Natco Pharma Limited ("Natco") for infringement of two of Shire's patents: U.S. Patent No. 5,968,976 ("'976 Patent"); and U.S. Patent No. 7,381,428 ("'428 Patent");

The lawsuit was filed in response to an ANDA (Abbreviated New Drug Application) filed by Natco seeking FDA approval to market and sell generic versions of Shire's 500 mg, 750 mg, and 1 g FOSRENOL(R) (Lanthanum Carbonate) products.

Under the Hatch-Waxman Act, because Shire filed its patent infringement lawsuit within 45 days of receiving Natco's Paragraph IV notification letter, the FDA must refrain from approving Natco's ANDA for 30 months, or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier. The stay on generic approval will expire on April 26, 2012 unless terminated earlier.

Shire has asserted the '976 and '428 patents based upon information provided to it by Natco. Shire will continue to evaluate the situation throughout the litigation and will take all necessary actions to protect its rights to the fullest extent possible. Shire has a robust patent estate and is confident that it will protect the FOSRENOL franchise.

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... the Georgia Institute of Technology have made important findings ... an electrical field on a surface-supported gold nanocluster changes ... flat structure. In another paper, they relate their discovery ... magnetic through oxygenation of gold nanowires. They also found ...
... ETEX Corporation, an advanced,biomaterials company, announced today that ... Health, Inc., Under the agreement, LifeNet Health ... to be mixed with ETEX,s proprietary,calcium phosphate to ... will manufacture EquivaBone(TM) in its Cambridge,facilities and market ...
... IOMI ) today announced that it will release fourth ... and hold a,conference call and live webcast to discuss ... 1:30 p.m. Eastern Time., Conference Call Details, ... 6 at 1:30 p.m.,Eastern Time via phone, please dial ...
Cached Biology Technology:Physicists discover gold can be magnetic on the nanoscale 2Physicists discover gold can be magnetic on the nanoscale 3Physicists discover gold can be magnetic on the nanoscale 4ETEX and LifeNet Health, Inc. Enter Agreement 2Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6 2
(Date:7/28/2014)... wild relative of the domestic tomato, has been published ... headed by Professors Neelima Sinha and Julin Maloof at ... genome information may help breeders produce tastier, more stress-tolerant ... journal Nature Genetics , was lead by Bjrn ... UC Davis labs carried out work on the transcriptome ...
(Date:7/28/2014)... of a new study suggest two ways to effectively address ... well in obese women, compared to women of a normal ... method, researchers say, but as the population has increased in ... for obese women. Studies have consistently found that obesity has ... may in turn affect how well the pill prevents pregnancy. ...
(Date:7/28/2014)... Jude Children,s Research Hospital study found that 73 percent ... their risk of developing metabolic syndrome and related health ... results appear in the current issue of the journal ... 1,598 adult survivors of childhood cancer in the study ... factors like high blood pressure, abdominal obesity, elevated triglyceride ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... dominates a plant,s growth principally because it was there first, ... the plant. Collaborating teams from the University of ... Canada combined their expertise in molecular genetics and computational modelling ... encourages plants to thrive. Understanding of the action and ...
... , , , ... that a new market research report is available in its catalogue. ... Market , , http://www.reportlinker.com/p0119500/World-Dynamic-Signature-Verification-Market.html ... for Dynamic Signature Verification in US$ Thousands. The market for Dynamic ...
... RESTON, Virginia, September 17 WCC Smart Search ... for multi-modal fusion, today,announced that it has been selected ... their driver registration system. ELISE ID will be used,to ... existing databases,that contain over 20 million records. It will ...
Cached Biology News:Explaining why pruning encourages plants to thrive 2Reportlinker Adds World Dynamic Signature Verification Market Report 2Reportlinker Adds World Dynamic Signature Verification Market Report 3Reportlinker Adds World Dynamic Signature Verification Market Report 4Reportlinker Adds World Dynamic Signature Verification Market Report 5Reportlinker Adds World Dynamic Signature Verification Market Report 6Reportlinker Adds World Dynamic Signature Verification Market Report 7Reportlinker Adds World Dynamic Signature Verification Market Report 8Reportlinker Adds World Dynamic Signature Verification Market Report 9
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Kinase Buffer can be used to assay protein kinase activity...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: